Navitoclax with ruxolitinib for myelofibrosis

Navitoclax in combination with ruxolitinib is currently in clinical development for the treatment
of intermediate-2 or high-risk primary myelofibrosis (PMF), post polycythemia vera myelofibrosis
or post-essential thrombocythemia myelofibrosis. Myelofibrosis is a rare blood cancer that causes
scarring of the bone marrow, which makes it more difficult to produce blood cells. The clinical
features of myelofibrosis are variable. Allogeneic hematopoietic cell transplant is currently the
only curative method. The current standard of care for those unsuitable for stem cell transplant
is treatment with ruxolitnib. However, many patients do not achieve an adequate response to this
drug, and significant residual symptoms remain. There is, therefore, an urgent need for an
improvement in therapeutic approaches for myelofibrosis.